Antimicrobial Residues and Antimicrobial-Resistant Bacteria: Impact on the Microbial Environment and Risk to Human Health-A Review

Human and Ecological Risk Assessment

Volumn 18, Issue 4, 2012, Pages 767-809

  Harris, Suvi J ^a   Cormican, Martin ^b   Cummins, Enda ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

antimicrobial resistance; pharmaceuticals; residue; therapeutic failure

Indexed keywords

BACTERIA (MICROORGANISMS); PROTOZOA;

EID: 84863815459     PISSN: 10807039     EISSN: 15497860     Source Type: Journal    
DOI: 10.1080/10807039.2012.688702     Document Type: Article

References (186)

1. Abellán, M N, Giménez, J and Esplugas, S. 2009. Photocatalytic degradation of antibiotics: The case of sulfamethoxazole and trimethoprim. Catal Today, 144: 131-6.
2. Adak, G K, Long, S M and O'Brien, S J. 2002. Trends in indigenous foodborne disease and deaths, England and Wales: 1992 to 2000. Gut, 51: 832-41.
3. Adams, C, Wang, YLoftin, K. 2002. Removal of antibiotics from surface and distilled water in conventional water treatment processes. J Environ Eng, 128(3): 253-60.
4. Adkinson, N F Jr, Essayan, DGruchalla, R. 2002. Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol, 109(3): S461-78.
5. Agwuh, K N and MacGowan, A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother, 58: 256-65.
6. Alexander, T W, Yanke, L JTopp, E. 2008. Effect of subtherapeutic administration of antibiotics on the prevalence of antibiotic-resistant Escherichia coli bacteria in feedlot cattle. Appl Environ Microbiol, 74(14): 4405-16.
7. Anderson, P D, D'Aco, V JShanahan, P. 2004. Screening analysis of human pharmaceutical compounds in U.S. surface waters. Environ Sci Technol, 38(3): 838-49.
8. Andersson, D I and Hughes, D. 2010. Antibiotic resistance and its cost: Is it possible to reverse resistance?. Nat Rev Microbiol, 8: 260-71.
9. Andreozzi, R, Raffaele, M and Nicklas, P. 2003. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere, 50: 1319-30.
10. Backhaus, T and Grimme, L H. 1999. The toxicity of antibiotic agents to the luminescent bacterium Vibrio fischeri. Chemosphere, 38: 3291-301.
11. Baiden, F, Owusu-Agyei, SWebster, J. 2010. The need for new antibiotics. Lancet, 375(9715): 637-8.
12. Baker, N and Hawkey, P. 2004. "The management of resistant Acinetobacter infections in the intensive therapy unit". In Management of Multiple Drug-Resistant Infections, Edited by: Gillespie, S H. Totowa, New Jersey, USA: Humana Press, Inc. NY, USA
13. Baquero, F, Martinez, J-L and Canton, R. 2008. Antibiotics and antibiotic residues in water environments. Curr Opin Biotechnol, 19: 260-5.
14. Batt, A L, Kim, S and Aga, D S. 2007. Comparison of the occurrence of antibiotics in four full-scale wastewater treatment plants with varying designs and operations. Chemosphere, 68: 428-35.
15. Blanc, D S, Pittet, DRuef, C. 2002. Epidemiology of methicillin-resistant Staphylococcus aureus: Results of a nation-wide survey in Switzerland. Swiss Med Wkly, 132: 223-9.
16. Boon, N, Goris, JDe Vos, P. 2001. Genetic diversity among 3-chloroaniline- and aniline degrading strains of the Comamonadaceae. Appl Environ Microbiol, 67: 1107-15.
17. Börjesson, S, Melin, SMatussek, A. 2009. A seasonal study of the mecA gene and Staphylococcus aureus including methicillin-resistant S. aureus in a municipal wastewater treatment plant. Water Res, 43: 925-32.
18. Boucher, H W, Talbot, G HBradley, J S. 2009. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis, 48(1): 1-12.
19. Bound, J P and Voulvoulis, N. 2004. Pharmaceuticals in the aquatic environment-a comparison of risk assessment strategies. Chemosphere, 56: 1143-55.
20. Bound, J P and Voulvoulis, N. 2005. Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United Kingdom. Environ Health Perspect, 113(12): 1705-11.
21. Bound, J P, Kitsou, K and Voulvoulis, N. 2006. Household disposal of pharmaceuticals and perception of risk to the environment. Environ Toxicol Pharmacol, 21: 301-7.
22. Boxall, A BA, Johnson, PSmith, E J. 2006. Uptake of veterinary medicines from soils into plants. J Agric Food Chem, 54: 2288-97.
23. Brown, K D, Kulis, JThomson, B. 2005. Occurrence of antibiotics in hospital, residential, and dairy effluent, municipal wastewater, and the Rio Grande in New Mexico. Sci Total Environ, 366: 772-83.
24. Bryskier, A. 2005. Antimicrobial Agents: Antibacterials and Antifungals, 1-13. 113-222. 475-642. Washington, DC, USA: ASM Press.
25. Burkholder, J, Libra, BWeyer, P. 2007. Impacts of waste from concentrated animal feeding operations on water quality. Environ Health Perspect, 115(2): 308-12.
26. Castiglioni, S, Bagnati, RCalamari, D. 2005. A multiresidue analytical method using solid-phase extraction and high-pressure liquid chromatography tandem mass spectrometry to measure pharmaceuticals of different therapeutic classes in urban wastewaters. J Chromatogr A, 1092: 206-15.
27. Castiglioni, S, Bagnati, RFanelli, R. 2006. Removal of pharmaceuticals in sewage treatment plants in Italy. Environ Sci Technol, 40: 357-63.
28. Celiz, M D, Tso, J and Aga, D S. 2009. Pharmaceutical metabolites in the environment: Analytical challenges and ecological risks. Environ Toxicol Chem, 28: 2473-84.
29. Chatzitakis, A, Berberidou, CPaspaltsis, I. 2008. Photocatalytic degradation and drug activity reduction of Chloramphenicol. Water Res, 42: 386-94.
30. Chin, N-X and Neu, H C. 1983. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother, 24: 754-63.
31. Chin, N-X and Neu, H C. 1984. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother, 25: 319-26.
32. Chopra, I and Roberts, M. 2001. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev, 65(2): 232-60.
33. Christian, T, Schneider, R JFärber, H A. 2003. Determination of antibiotic residues in manure, soil and surface waters. J Environ Qual, 34: 1363-71.
34. Clara, M, Strenn, BAusserleitner, M. 2004. Comparison of the behaviour of selected micropollutants in a membrane bioreactor and a conventional wastewater treatment plant. Water Sci Technol, 50(5): 29-36.
35. Cornaglia, G. 2009. Fighting infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect, 15(3): 209-11.
36. Cornett, J B, Wagner, R BDobson, R A. 1985. In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin). Antimicrob Agents Chemother, 27: 4-10.
37. Cosgrove, SE. 2006. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis, 42: S82-S89.
38. Cummins, EJ. 2008. The role of quantitative risk assessment in the management of foodborne biological hazards. Int J Risk Assess Manage, 8(3): 318-30.
39. Cunningham, V L, Binks, S P and Olson, M J. 2009. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Reg Toxicol Pharm, 53: 39-45.
40. Dagan, R, Barkai, GGivon-Lavi, N. 2008. Seasonality of antibiotic-resistant Streptococcus pneumoniae that causes acute otitis media: A clue for an antibiotic-restriction policy?. J Infect Dis, 197: 1094-102.
41. Daughton, C G and Ternes, T A. 1999. Pharmaceuticals and personal care products in the environment: Agents of subtle change? Environ. Health Perspect, 107: 907-38.
42. Deshpande, A D, Baheti, K G and Chatterjee, N R. 2004. Degradation of β-lactam antibiotics. Curr Sci, 87(12): 1684-95
43. DeWitte, B, Dewulf, JDemeestere, K. 2008. Ozonation of ciprofloxacin in water: HRMS identification of reaction products and pathways. Environ Sci Technol, 42: 4889-95.
44. Díaz-Cruz, M S and Barceló, D. 2006. Determination of antimicrobial residues and metabolites in the aquatic environment by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem, 386: 973-85.
45. Diehl, D L and LaPara, T M. 2010. Effect of temperature on the fate of genes encoding tetracycline resistance and the integrase of class 1 integrons within anaerobic and aerobic digesters treating municipal wastewater solids. Environ Sci Technol, 44(23): 9128-33.
46. Dijkshoorn, L, Nemec, A and Seifert, H. 2007. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol, 5: 939-951.
47. Doi, A M and Stoskopf, M K. 2000. The kinetics of oxytetracycline degradation in deionized water under varying temperature, pH, light, substrate, and organic matter. J Aquatic Anim Health, 12: 246-53.
48. Doi, Y, Husain, SPotoski, B A. 2009. Extensively drug-resistant Acinetobacter baumannii. Emerging Infect Dis, 15: 980
49. Doll, T E and Frimmel, F H. 2003. Fate of pharmaceuticals-photodegradation by simulated solar UV-light. Chemosphere, 52: 1757-69.
50. Drews, J. 2000. Drug discovery: A historical perspective. Science, 287: 1960-4.
51. EARSS (Antimicrobial Resistance Surveillance System). 2010. EARS-NET Report for Quarter. 1: 2020 Available at http://www.ndsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EARSSSurveillanceReports/2010Reports/File,4412,en.pdf
52. ECDC (European Centre for Disease Prevention and Control). 2008. Summary of Latest EU-wide Data on Antibiotic Resistance and Antibiotic Consumption. Available at http://www.sante.public.lu/publications/rester-bonne-sante/medicaments/summary-eu-data-antibiotic-resitance-consumption/summary-eu-data-antibiotic-resitance-consumption.pdf
53. ECOSAR (Ecological Structure Activity Relationships). 2009. "Ecowin v. 1.00a, ECOSAR Classes for Microsoft windows". In US Environmental Protection Agency, OPPT Risk Assessment Division Washington, DC, USA
54. EEA (European Environment Agency). 2010. Pharmaceuticals in the Environment- Results of an EEA Workshop. Available at http://www.eea.europa.eu/publications/pharmaceuticals-in-the-environment-result-of-an-eea-workshop
55. Elmolla, E S and Chaudhuri, M. 2010. Photocatalytic degradation of amoxicillin, ampicillin and cloxacillin antibiotics in aqueous solution using UV/TiO2 and UV/H2O2/TiO2 photocatalysis. Desalination, 252: 46-52.
56. El-Shaboury, S R, Saleh, G AMohamed, F A. 2007. Analysis of cephalosporin antibiotics. J Pharm Biomed Anal, 45: 1-19.
57. EMEA (European Medicines Agency). 2006. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. The European Agency for the Evaluation of Medicinal Products, London England. Available at http://www.emea.europa.eu/pdfs/human/swp/444700en.pdf
58. EPA (Environmental Protection Agency). 2006. Guidance on Environmental Liability Risk Assessment, Wexford, Ireland: Residuals Management Plans and Financial Provisions. Available at http://www.epa.ie/downloads/advice/licensee/ELRA%20Guidance%20Document.pdf
59. Europa. 2005. Ban on Antibiotics as Growth Promoters in Animal Feed Enters into Effect. Available at http://europa.eu/rapid/pressReleasesAction.do?reference=IP/05/ 1687&format=HTML&aged=0&language=EN&guiLanguage=en
60. ESAC (European Surveillance of Antimicrobial Consumption). 2008. Antimicrobials for Systemic Use. Available at http://www.esac.ua.ac.be/main.aspx?c=*ESAC2&n=50255
61. ESAC. (interactive database). 2009. Available at http://www.esac.ua.ac.be/esac_service/applet/eidb.html
62. Fasani, E, Profumo, A and Albini, A. 1998. Structure and medium-dependent photodecomposition of fluoroquinolone antibiotics. Photochem Photobiol, 68: 666-74.
63. FDA (Food and Drug Administration). 2003. Guidance for Industry Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern document 152. Available at http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM052519.pdf
64. FDA. 2009. Cumulative Estimated Daily Intake/Acceptable Daily Intake Database. Available at http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?rpt=cediListing
65. Feitosa-Felizzola, J and Chiron, S. 2008. Occurrence and distribution of selected antibiotics in a small Mediterranean stream (Arc River, Southern France). J Hydrol, 364: 50-7.
66. Fent, K, Weston, A A and Caminada, D. 2006. Ecotoxicology of human pharmaceuticals. Aquatic Toxicol, 76: 122-59.
67. Ferech, M, Coenen, SMalhotra-Kumar, S. 2006. European surveillance of antimicrobial consumption (ESAC): Outpatient antibiotic use in Europe. J Antimicrob Chemother, 58: 401-7.
68. Fick, J, Söderström, HLindberg, R H. 2009. Contamination of surface, ground, and drinking water from pharmaceutical production. Environ Toxicol Chem, 28(12): 2522-7.
69. Focazio, M J, Kolpin, D WBarnes, K B. 2008. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States-II) Untreated drinking water sources. Sci Total Environ, 402: 201-16.
70. Fraunfelder, F W and Fraunfelder, F T. 2009. Diplopia and fluoroquinolones. Ophthalmol, 116(9): 1814-7.
71. Galvin, S, Boyle, FHickey, P. 2010. Enumeration and characterization of antimicrobial-resistant Escherichia coli bacteria in effluent from municipal, hospital, and secondary treatment facility sources. Appl Environ Microbial, 76(14): 4772-9.
72. Gartiser, S, Urich, EAlexy, R. 2007. Ultimate biodegradation and elimination of antibiotics in inherent tests. Chemosphere, 67(3): 604-13.
73. George, I, Crop, P and Servais, P. 2002. Fecal coliform removal in wastewater treatment plants studied by plate counts and enzymatic methods. Water Res, 36: 2607-17.
74. Giamarellou, H. 2002. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother, 49: 229-33.
75. Giger, W, Alfredo, CGolet, E M. 2003. Occurrence and fate of antibiotics as trace contaminants in wastewaters, sewage sludge, and surface waters. Chimia, 57: 485-91.
76. Giraldo, A L, Peñuela, G ATorres-Palma, R A. 2010. Degradation of the antibiotic oxolinic acid by photocatalysis with TiO2 in suspension. Water Res, 44: 5158-67.
77. Göbel, A, Thomsen, AMcArdell, C S. 2005. Extraction and determination of sulfonamides, macrolides, and trimethoprim in sewage sludge. J Chromatogr A, 1085(22): 179-89.
78. González, O, Sans, C and Esplugas, S. 2007. Sulfamethoxazole abatement by photo-fenton: Toxicity, inhibition and biodegradability assessment of intermediates. J Haz Mat, 146: 459-64.
79. Goossens, H, Ferech, MVander Stichele, R. 2005. Outpatient antibiotic use in Europe and association with resistance: A cross national database. Lancet, 365: 578-87.
80. Graham, J E, Wilcox, L W and Graham, L E. 2008. Algae, 2nd edit. Pearson Benjamin Cummings San Francisco, CA, USA
81. Guardabassi, L, Lo Fo Wong, D MA and Dalsgaard, A. 2002. The effects of tertiary wastewater treatment on the prevalence of antimicrobial resistant bacteria. Water Res, 36: 1955-64.
82. Guerrero-Preston, R and Brandt-Rauf, P. 2008. Pharmaceutical residues in the drinking water supply: Modelling residue concentrations in surface waters of drugs prescribed in the United States. Puerto Rico Health Sci J, 20(3): 236-40.
83. Hanisch, B, Abbas, B and Kratz, W. 2002. Öktoxikologische Bewertung von Humanarzneimitteln in aquatischen Ökosystemen, Potsdam: Landesumweltamt.
84. Harder, S, Fuhr, UBeermann, D. 1990. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol, 30(1): 35-9.
85. Hartmann, A, Alder, A CKoller, T. 1998. Identification of fluoroquinolone antibiotics as the main source of umuC genotoxicity in native hospital wastewater. Environ Toxicol Chem, 17(3): 377-82.
86. Hawkey, PM. 2008. The growing burden of antimicrobial resistance. J Antimicrob Chemother, 62: i1-i9.
87. Hawkey, P M and Jones, A M. 2009. The changing epidemiology of resistance. J Antimicrob Chemother, 64: i3-i10.
88. Hernando, M D, Mezcua, MFernandez-Alba, A R. 2006. Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta, 69: 334-42.
89. Hilton, M J and Thomas, K V. 2003. Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A, 1015: 129-41.
90. Hirsch, R, Ternes, THaberer, K. 1999. Occurrence of antibiotics in the aquatic environment. Sci Total Environ, 225: 109-18.
91. HPSC (Health Protection Surveillance Centre). 2008. Annual Report 2008. Available at http://www.hpsc.ie/hpsc/AboutHPSC/AnnualReports/File,4080,en.pdf
92. HSE (Health Services Executive). 2007. HSE Corporate Publications: Review of 2007: Population Health. Available at http://www.hse.ie/eng/services/Publications/corporate/html/Corporate/2007/Population_Health.html
93. Hu, D and Coats, J R. 2007. Aerobic degradation and photolysis of tylosin in water and soil. Environ Toxicol Chem, 26: 884-9.
94. Hurd, S, Doores, SHayes, D. 2004. Public health consequences of macrolide use in food animals: A deterministic risk assessment. J Food Protection, 67(5): 980-92.
95. Idsoe, O, Guthe, TWilcox, R R. 1968. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull WHO., 38: 159-88.
96. IISG (Illinois-Indiana Sea Grant). 2007. Disposal of Unwanted Medicines: A Resource for Action in Your Community. Available at http://www.iisgcp.org/unwantedmeds/toolkit/europeanunion.pdf
97. Institute of Medicine. 1998. Antimicrobial Resistance: Issues and Options. Workshop Report, pp 104, Washington, DC, USA: National Academies Press.
98. Jonsson, M, Walder, M and Forsgren, A. 1990. First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandinavia. European J Clin Microbiol Infect Dis, 9(11): 851-3.
99. Joss, A, Keller, EAlder, A C. 2005. Removal of pharmaceuticals and fragrances in biological wastewater treatment. Water Res, 39(14): 3139-52.
100. Junker, T, Alexy, RKnacker, T. 2006. Biodegradability of 14C-Labeled antibiotics in a modified laboratory scale sewage treatment plant at environmentally relevant concentrations. Environ Sci Technol, 40: 318-24.
101. KarcI, A and BalcIoglu, I A. 2009. Investigation of the tetracycline, sulfonamide, and fluoroquinolone antimicrobial compounds in animal manure and agricultural soils in Turkey. Sci Total Environ, 407(16): 4652-64.
102. Kashido, Y and Kato, M. 1997. Characterisation of fluoroquinolone-induced Achilles tendon toxicity in rats: Comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother, 41: 2389-93.
103. Keller, V. 2006. Risk assessment of down-the-drain chemicals: Search for a suitable model. Sci Total Environ, 360: 305-18.
104. Kemper, N. 2008. Veterinary antibiotics in the aquatic and terrestrial Environment. Ecolog Indicat, 8: 1-13.
105. Kim, K-R, Owens, GKwon, S-I. 2011. Occurrence and environmental fate of veterinary antibiotics in the terrestrial environment. Water, Air, Soil Pollut, 214: 163-74.
106. Kim, S and Aga, D S. 2007. Potential ecological and human health impacts of antibiotics and antibiotic-resistant bacteria from wastewater treatment plants. J Toxicol Environ Health, 10: 559-73.
107. Kim, S D, Cho, JKim, I S. 2007. Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste waters. Water Res, 41(5): 1013-21.
108. Knapp, C W, Dolfing, JEhlert, P AI. 2010. Evidence of Increasing Antibiotic Resistance Gene Abundances in Archived Soils since 1940. Environ Sci Technol, 44: 580-7.
109. Kolpin, D W, Furlong, E TMeyer, T M. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: A national reconnaissance. Environ Sci Technol, 36(6): 1202-11.
110. Koschorreck, J, Koch, C and Rönnefahrt, I. 2002. Environmental risk assessment of veterinary medicinal products in the EU-A regulatory perspective. Toxicol Lett, 131: 117-24.
111. Kümmerer, K. 2003. Significance of antibiotics in the environment. J Antimicrob Chemother, 52: 5-7.
112. Kümmerer, K. 2004. Resistance in the environment. J Antimicrob Chemother, 54(2): 311-20.
113. Kümmerer, K. 2008. Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks, 7-17. 133-142. 160-162. 182-197. 211-227. 240-427. Berlin, Heidelberg, New York,: Springer. 435, 1. Auflage
114. Kümmerer, K. Oral communication. March 31, 2010. EPA SRIVE Programme (2007-2013), Steering Committee Meeting, EPA, Dublin, Ireland,
115. Lalumera, G M, Calamari, DGalli, P. 2004. Preliminary investigation on the environmental occurrence and effects of antibiotics used in aquaculture in Italy. Chemospher, 54: 661-8.
116. Lampen, A, Zhang, YHackbarth, I. 1998. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exper Therapeutics, 285: 1104-12. Christians U.
117. Larsson, D GJ, de Pedro, C and Paxeus, N. 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater, 148: 751-5.
118. Leeder, JS. 1998. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia, 39(7): S8-S16.
119. Li, D, Yang, MHu, J. 2008. Determination of penicillin G and its degradation products in a penicillin production wastewater treatment plant and the receiving river. Water Res, 42: 307-17.
120. Lin, RY. 1992. A perspective on penicillin. Allergy Arch Intern Med, 152: 930-7.
121. Lindberg, Rh, Bjorklund, KRendahl, P. 2007. Environmental risk assessment of antibiotics in the Swedish environment with emphasis on sewage treatment plants. Water Res, 41: 613-9.
122. Loftin, K A, Henny, CAdams, C D. 2005. Inhibition of microbial metabolism in anaerobic lagoons by selected sulfonamides, tetracyclines, lincomycin, and tylosin tartrate. Environ Toxicol Chem, 24(4): 782-8.
123. Loftin, K A, Adams, C DMeyer, M T. 2008. Effects of ionic strength, temperature, and pH on degradation of selected antibiotics. J environ qual, 37: 378-86.
124. Madigan, M T, Martinko, J MDunlap, P V. 2008. Brock Biology of Microorganisms, 12th edit, San Francisco, CA, USA: Pearson Benjamin Cummings.
125. Manaia, C, Novo, ACoelho, B. 2010. Ciprofloxacin resistance in domestic wastewater treatment plants. Water, Air, Soil Pollut, 208: 335-43.
126. Mancini, P, Fertels, SNave, D. 1987. Mobilization of plasmid pHSV106 from Escherichia coli HB101 in a laboratory-scale waste treatment facility. Appl Environ Microbiol, 53: 665-71.
127. Mathew, A G, Cissell, R and Liamthong, S. 2007. Antibiotic resistance in bacteria associated with food animals: A United States perspective of livestock production. Foodborne Pathog Dis, 4(2): 115-33.
128. McGowan, B, Bergin, CBennett, K. 2008. Utilisation of antibiotic therapy in community practice. Irish Med J, 101(9): 273-76.
129. Mendez, A, Chagastelles, PPalma, E. 2008. Thermal and alkaline stability of meropenem: Degradation products and cytotoxicity. Intl J Pharm, 350: 95-102.
130. Mesaros, N, Nordmann, P and Plésiat. 2007. Pseudomonas aeruginosa: Resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect, 13: 560-78.
131. Moreno, E, Macías, EDávila, I. 2008. Hypersensitivity reactions to cephalosporins. Expert Opin Drug Saf, 7(3): 295-304.
132. Nakada, N, Tanishima, TShinohara, H. 2006. Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. Water Res, 40(17): 3297-303.
133. National Disease Surveillance Centre of Ireland. 2004. Antibiotic Consumption in Ireland, 1993-2002. Epi-insight,: 2-3. Available at http://www.hpsc.ie/hpsc/EPI-Insight/Volume52004/File,681,en.PDF
134. Nordmann, P, Naas, TFortineau, N. 2007. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol, 10: 436-40.
135. O'Brien, E and Dietrich, D R. 2004. Hindsight rather than foresight: Reality versus the EU draft guideline on pharmaceuticals in the environment. Trends Biotechnol, 22(7): 326-30.
136. Ohlsen, K, Ziebuhr, WKoller, K. 1998. Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother, 42: 2817-23.
137. Page, M G and Heim, J. 2009. Prospects for the next anti-Pseudomonas drug. Curr Opinion Pharmacol, 9(5): 558-65.
138. Park, BK. 1992. Idiosyncratic drug reactions: A mechanistic evaluation of risk factors. Br J Clin Pharmacol, 34(5): 377-95.
139. Park, S and Choi, K. 2008. Hazard assessment of commonly used agricultural antibiotics on aquatic ecosystems. Ecotoxicology, 17(6): 526-38.
140. Payment, P, Plante, R and Cejka, P. 2001. Removal of indicator bacteria, human enteric viruses, Giardia cysts, and Cryptosporidium oocysts at a large wastewater primary treatment facility. Canadian J Microbiol, 47(3): 188-93.
141. Pena, C, Albareda, J MPallares, R. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother, 39(2): 520-4.
142. Perez, F, Hujer, A MHujer, K M. 2007. Global challenge of multidrug-resistant acinetobacter baumannii. antimicrob agents. Chemother, 51: 3471-84.
143. Poole, K. 2011. Pseudomonas aeruginosa: Resistance to the max. Front Microbiol, 2(65): 1-13.
144. Rauch, W and Harremoes, P. 1996. The importance of the treatment plant performance during rain to acute water pollution. Water Sci Technol, 34(3-4): 1-8.
145. Riddle, C, Lemons, C LPapich, M G. 2000. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing. J Clin Microbiol, 38(4): 1636-7.
146. Sarmah, A K, Meyer, M T and Boxall, A BA. 2006. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. Chemosphere, 65: 725-59.
147. SCC (Stockholm County Council). 2009. Environmentally Classified Pharmaceuticals. Available at http://www.noharm.org/lib/downloads/pharmaceuticals/Envir_Classified_Pharmaceuticals.pdf
148. Schlüter, A, Szczepanowski, RPühler, A. 2007. Genomics of IncP-1antibiotic resistance plasmids isolated from wastewater treatment plants provides evidence for a widely accessible drug resistance gene pool. Federation of European Microbiological Societies Microbiol Rev, 31: 449-77.
149. Schowanek, D and Webb, S. 2002. Exposure simulation for pharmaceuticals in European surface waters with GREAT-ER. Toxicol Lett, 131: 39-50.
150. Schwab, B W, Hayes, E PFiori, J M. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol, 42(3): 296-312.
151. Sedlak, D L and Pinkston, K E. 2001. Factors affecting the concentrations of pharmaceuticals released to the aquatic environment. Water Resour Update, 120: 56-64.
152. Silva, J, Castillo, GCallejas, L. 2006. Frequency of transferable multiple antibiotic resistance amongst coliform bacteria isolated from a treated sewage effluent in Antofagasta, Chile. J Biotechnol, 9(5): 533-40.
153. Sirés, I, Garrido, J ARodríguez, R M. 2007. Catalytic behavior of the Fe3+/Fe2+ system in the electro-Fenton degradation of the antimicrobial chlorophene. Appl Catal B, 72: 382-94.
154. Snarly, E L, Kelly, L ADavison, H C. 2004. Antimicrobial resistance: A microbial risk assessment perspective. J Antimicrob Chemother, 53: 906-17.
155. Spellberg, B, Guidos, RGilbert, D. 2008. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the infectious diseases society of America. Clin Infect Dis, 46: 155-64.
156. Stahlmann, R and Lode, H. 1988. Safety Overview: Toxicity, Adverse Effects and Drug Interaction. The Quinolones, 201-35. London, UK: Academic Press, Ltd.
157. Ternes, T. 1998. Occurrence of drugs in German sewage treatment plants and rivers. Water Res, 32(11): 3245-60.
158. Ternes, T A, Meisenheimer, MMcDowell, D. 2002. Removal of pharmaceuticals during drinking water treatment. Environ Sci Technol, 36(17): 3855-63.
159. Thomas, K V, Dye, CSchlabach, M. 2007. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Mon, 9: 1410-8.
160. Travers, K and Barza, M. 2002. Morbidity of infections caused by antimicrobial-resistant bacteria. Clin Infect Dis, 34: 131-4.
161. Turkdogan, F I and Yetilmezsoy, K. 2009. Appraisal of potential environmental risks associated with human antibiotic consumption in Turkey. J Haz Mat, 166: 297-308.
162. Van den Bogaard, A. 2000. Epidemiology of resistance to antibiotics links between animals and humans. Int J Antimicrob Agents, 14(4): 327-35.
163. Van der Linden, P D, Van de Lei, JNab, H W. 1999. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol, 48: 433-7.
164. Van der Linden, P D, Sturkenboom, MCJMHerings, R MC. 2002. Fluoroquinolones and risk of Achilles tendon disorders: Case control study. BMJ, 321: 1306-7.
165. Vasconcelos, T G, Henriques, D MKönig, A. 2009. Photo-degradation of the antimicrobial ciprofloxacin at high pH: Identification and biodegradability assessment of the primary by-products. Chemosphere, 76: 487-93.
166. Vellinga, A, Murphy, A WHanahoe, B. 2010. A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother, 65(7): 1514-20.
167. Vose, D. 2008. Risk Analysis a Quantitative Guide, 3rd edit, 80-8. New Yor, NY, USA: John Wiley and Sons, Ltd.
168. Water, UK. 2006. Wastewater Treatment and Recycling. Available at http://www.water.org.uk/home/news/press-releases/wastewater-pamphlet/wastewater-web-2-.pdf
169. Watkinson, A J, Murby, E J and Costanzo, S D. 2007. Removal of antibiotics in conventional and advanced wastewater treatment: Implications for environmental discharge and wastewater recycling. Water Res, 41: 4164-76.
170. Weinstein, L and Kaplan, K. 1970. The cephalosporins. Microbiology chemical and pharmaceutical properties and use in chemotherapy of infection. Ann Inter Med, 72: 729-39.
171. Werner, J J, Arnold, W A and McNeill, K. 2006. Water hardness as a photochemical parameter: Tetracycline photolysis as a function of calcium concentration, magnesium concentration, and pH. Environ Sci Technol, 40: 7236-41.
172. Wernli, D, Haustein, TConly, J. 2011. A call for action: The application of the international health regulations to the global threat of antimicrobial resistance. PLoS Med, 8(4): e1001022
173. WHO (World Health Organisation). 1997. Antimicrobial resistance monitoring programme. WHO Drug Information., 11: 248-9.
174. WHO. 2002. Antimicrobial Resistance Fact Sheet No. 194. Available at http://www.who.int/mediacentre/factsheets/fs194/en/print.html
175. Williams, H, Stewart, Avon Mutius, E. 2008. Is eczema really on the increase worldwide?. J Allergy Clin Immunol, 121(4): 947-54. e15
176. Wright, GD. 2010. Antibiotic resistance in the environment: A link to the clinic?. Curr Opin Microbiol, 13: 589-94.
177. Wu, J WJ, Jiang, Y JYZha, L ZL. 2010. Tetracycline degradation by ozonation, and evaluation of biodegradability and toxicity of ozonation byproducts. Can J Civ Eng, 37: 1485-91.
178. Xu, W, Zhang, GLi, X. 2007. Occurrence and elimination of antibiotics at four sewage treatment plants in the Pearl River Delta (PRD), South China. Water Res, 41(19): 4526-34.
179. Zavascki, A P, Carvalhaes, C GPicão, R C. 2010. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev Anti-Infect Ther, 8: 71-93.
180. Zepp, R G and Cline, D M. 1977. Rates of direct photolysis in aquatic environment. Environ Sci Technol, 11: 359-66.
181. Zhang, Y, Marrs, C FSimon, C. 2009. Wastewater treatment contributes to selective increase of antibiotic resistance among Acinetobacter spp. Sci Total Environ, 407: 3702-6.
182. Zorita, S, Mårtensson, L and Mathiassona, L. 2009. Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden. Sci Total Environ, 407: 2760-70.
183. Zuccato, E, Castiglioni, S and Fanelli, R. 2005. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J Hazar Mater, 122(3): 205-9
184. Zuccato, E, Castiglioni, SFanelli, R. 2006. Pharmaceuticals in the environment in Italy: Causes, occurrence, effects and control. Environ Sci Pollut Res, 13(1): 15-21.
185. Zuehlke, S, Duennbier, ULesjean, B. 2006. Long-term comparison of trace organics removal performances between conventional and membrane activated sludge processes. Water Environ Res, 78(13): 2480-6.
186. Zwiener, C and Frimmel, F H. 2000. Oxidative treatment of pharmaceuticals in water. Water Res, 34(6): 1881-5.